Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- -Clinical improvement consistently seen...

Related Keywords

Denmark ,United States ,Poland ,Copenhagen ,Køavn ,Stefan Schreiber ,Dan Cui ,Jaroslaw Kierkus ,Bruce Rogers ,Burrillb Crohn ,Sharon Brown ,Laurent Peyrin Biroulet ,Silvio Danese ,Peter Linde ,Oladele Babalola ,Ali Hussain ,Fangui Sun ,Maloy Mangada ,Brihad Abhyankar ,Carolyn Soo ,Chris Erdman ,Cuyue Tang ,Dooyoung Lee ,Yujun Wu ,Kerry Mcconie ,Pbruce Sands ,Adrian Ray ,Brian Feagan ,Michael Choi ,Sarah Hammer ,Globenewswire Inc ,Securities Exchange ,Mount Sinai Health System ,Henry Janowitz Division Of Gastroenterology ,Icahn School Of Medicine At Mount Sinai ,Exchange Commission ,United European Gastroenterology Week ,Robarts Histopathology Index ,Mayo Clinic Score ,Mount Sinai ,Henry Janowitz Division ,Modified Mayo Clinic Score ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,